Company news

Veracyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier

May 24, 2021

Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection

May 18, 2021

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

May 13, 2021

Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis

May 13, 2021

Veracyte, Inc. Announces CEO Succession Plan

May 9, 2021

Veracyte Announces First Quarter 2021 Financial Results

May 9, 2021

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

May 3, 2021

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO

April 28, 2021

Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis

April 26, 2021

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

April 19, 2021

Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference

April 18, 2021

Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

April 14, 2021

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

April 13, 2021

Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

April 1, 2021

Veracyte Appoints Muna Bhanji to Its Board of Directors

March 21, 2021

Veracyte Completes Acquisition of Decipher Biosciences

March 14, 2021

Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

February 16, 2021

Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

February 9, 2021

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 8, 2021

Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock

February 3, 2021

Veracyte Announces Proposed Public Offering of Common Stock

February 2, 2021

Veracyte Announces ISO 13485: 2016 Certification for Its In Vitro Diagnostics Quality Management System

December 20, 2020

Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

December 15, 2020

Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

December 14, 2020

Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

December 2, 2020

Veracyte Announces New General Manager Structure to Advance Global Expansion

November 16, 2020

Veracyte Announces Third Quarter 2020 Financial Results

November 1, 2020

Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance

October 29, 2020

Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier

October 21, 2020

Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020

October 18, 2020

Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020

October 13, 2020

Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020

October 6, 2020

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

September 23, 2020

Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director

September 13, 2020

Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests

September 10, 2020

Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year

August 23, 2020

Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases

August 4, 2020

Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock

August 3, 2020

Veracyte Announces Second Quarter 2020 Financial Results

July 29, 2020

Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System

July 28, 2020

Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary

July 26, 2020

Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020

July 15, 2020

Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis

June 10, 2020

Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay

June 8, 2020

Veracyte Announces First Quarter 2020 Financial Results

May 5, 2020

Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis

April 30, 2020

CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis

April 22, 2020

Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic

April 15, 2020

Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations

April 6, 2020

Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients

March 31, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.